|
Mar 27
|
Mesoblast (MESO) to File Pediatric GVHD Drug BLA, Stock Up
|
|
Mar 26
|
SEC Tests Insider-Trading Theory at Trial of Ex-Biotech Executive
|
|
Mar 12
|
Incyte (INCY) Posts Positive Results on Opzelura From HS Study
|
|
Mar 10
|
Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis
|
|
Mar 10
|
Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa
|
|
Mar 7
|
3 Cancer-Fighting Biotech Stocks Showing Clinical Trial Promise
|
|
Jan 15
|
IDEAYA Biosciences, Inc. (IDYA) Moves 7.6% Higher: Will This Strength Last?
|